Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Teva Pharmaceutical Industries Ltd (TEVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 17,465,040
  • Shares Outstanding, K 1,016,000
  • Annual Sales, $ 21,903 M
  • Annual Income, $ 329,000 K
  • 36-Month Beta 0.57
  • Price/Sales 0.80
  • Price/Cash Flow 2.60
  • Price/Book 0.67

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.22 +12.94%
on 09/06/17
20.10 -14.48%
on 09/12/17
+0.18 (+1.06%)
since 08/22/17
3-Month
15.22 +12.94%
on 09/06/17
33.82 -49.17%
on 07/13/17
-15.33 (-47.14%)
since 06/22/17
52-Week
15.22 +12.94%
on 09/06/17
51.51 -66.63%
on 09/23/16
-34.04 (-66.45%)
since 09/22/16

Most Recent Stories

More News
TEVA PHARMACEUTICAL SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Teva Pharmaceutical Industries Limited - (TEVA)

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 23, 2017 to file lead plaintiff applications in a securities class action lawsuit against Teva Pharmaceutical...

TEVA : 17.19 (+0.23%)
Cancer Space Update: Mixed Week for Pfizer, Roche Falters

Roche again disappointed this week with two studies on Tecentriq being put on partial hold while Pfizer's Bavencio received approval in Europe. TESARO's Zejula moved a step closer to approval.

MRK : 65.13 (-0.72%)
KPTI : 10.63 (+1.43%)
TSRO : 119.04 (+0.31%)
TEVA : 17.19 (+0.23%)
RHHBY : 32.0200 (-0.06%)
PFE : 35.96 (-0.03%)
Pharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update

Industry heavyweights like Pfizer (PFE) and Johnson & Johnson were in the news this week related to a lawsuit while Glaxo got FDA approval for a key drug.

JNJ : 131.39 (-0.27%)
SUPN : 39.00 (-1.02%)
TEVA : 17.19 (+0.23%)
RHHBY : 32.0200 (-0.06%)
PFE : 35.96 (-0.03%)
GSK : 40.58 (+0.62%)
BMY : 63.36 (+0.05%)
Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Teva Pharmaceutical Industries Ltd. Investors and Encourages Investors to Contact the Firm (TEVA)

Glancy Prongay & Murray LLP ("GPM") announces that a class action lawsuit has been filed on behalf of investors who purchased Teva Pharmaceutical Industries Ltd. ("Teva" or the "Company")...

TEVA : 17.19 (+0.23%)
EQUITY ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Reminds Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 21, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Teva Pharmaceutical Industries Limited ("Teva" or the "Company") (NYSE:...

TEVA : 17.19 (+0.23%)
Big Business Starting to Look at Canada's Newest Industry

Twenty years ago, it was vilified as a 'gateway drug'. Now, cannabis has grown into a big business, with the potential to become even bigger as laws are scheduled to change to reflect shifting social attitudes...

MEDFF : 7.3679 (-1.71%)
MO : 62.49 (+1.61%)
LEAF.TO : 9.14 (-1.19%)
INSY : 8.81 (-0.68%)
GWPH : 108.46 (-0.70%)
TEVA : 17.19 (+0.23%)
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Teva Pharmaceutical Industries Ltd. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Teva Pharmaceutical Industries Ltd. ("Teva" or the "Company") (NYSE: TEVA) of the October 23, 2017 deadline to seek the...

TEVA : 17.19 (+0.23%)
INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / September 20, 2017 / Khang & Khang LLP (the "Firm") announces the filing of a securities class action lawsuit against Teva Pharmaceutical Industries Limited ("Teva" or the "Company")...

TEVA : 17.19 (+0.23%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Teva Pharmaceutical Industries Ltd. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 23, 2017 - TEVA

The following statement is being issued by Levi & Korsinsky, LLP:

TEVA : 17.19 (+0.23%)
Teva/Nuvelution to Speed Up Development of Austedo in US

Teva Pharma (TEVA) and Nuvelution inked a deal to accelerate the development of Austedo (deutetrabenazine) tablets for the treatment of tics associated with Tourette syndrome.

HLUYY : 60.1180 (+2.89%)
TEVA : 17.19 (+0.23%)
REGN : 432.72 (-0.17%)
ALXN : 142.82 (-0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended...

See More

Support & Resistance

2nd Resistance Point 17.46
1st Resistance Point 17.32
Last Price 17.19
1st Support Level 17.05
2nd Support Level 16.92

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.